CH1251125998
© EQS Newswire
15.12.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
News Preview
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, prec......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The new...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.11.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
News Preview
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
GENEVA (Nov. 25, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and ra......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
14.11.2025
RLF
LISTED
SIX
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
News Preview
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Shareholders approve all EGM proposals related to the combination with NeuroX
Business combination expected to close in December 2025
Relief to be renamed MindMaze Therapeutics Holding SA upon closing
New board and executive committee members announced
Companies to host ......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
14.11.2025
RLF
LISTED
SIX
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
News Preview
Shareholders approve all EGM proposals related to the combination with NeuroXBusiness combination expected to close in December 2025Relief to be renamed MindMaze Therapeutics Holding SA upon closingNew board and executive committee members announcedCompanies to host joint press conference on November 25, 2025 GENEVA, SWITZERLAND / ACCESS Newswire /...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
News Preview
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
RLF-OD032 demonstrated bioequivalence to KUVAN® Powder
Study results support planned 505(b)(2) NDA submission in early 2026
GENEVA (OCT. 29, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceuti......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
News Preview
RLF-OD032 demonstrated bioequivalence to KUVAN® PowderStudy results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatme...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.10.2025
RLF
LISTED
SIX
Relief Therapeutics Convenes Extraordinary General Meeting
News Preview
Relief Therapeutics Convenes Extraordinary General Meeting
GENEVA (Oct. 24, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has convened an e......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.10.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
News Preview
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
Companies sign definitive agreement following previously announced binding term sheet
Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
Combined company to be renamed MindMaze Therapeuti......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.08.2025
RLF
LISTED
SIX
Relief Therapeutics Publishes 2025 Half-Year Report
News Preview
Relief Therapeutics Publishes 2025 Half-Year Report
GENEVA (AUG. 14, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year r......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.08.2025
RLF
LISTED
SIX
Relief Therapeutics Publishes 2025 Half-Year Report
News Preview
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a co...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.08.2025
RLF
LISTED
SIX
Relief Therapeutics Advances Publication of 2025 Half-Year Report
News Preview
Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relie......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
11.08.2025
RLF
LISTED
SIX
Relief Therapeutics Advances Publication of 2025 Half-Year Report
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.07.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
News Preview
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
Business combination to create an expanded, SIX-listed, commercial-stage, ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.07.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
News Preview
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disordersBusiness combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech companyBinding term sheet signed; transaction subject to customary...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.06.2025
RLF
LISTED
SIX
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
News Preview
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
GENEVA (June 20, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial r......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.06.2025
RLF
LISTED
SIX
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.06.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Results of Annual General Meeting
News Preview
Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces Results of Annual General Meeting
Shareholders approved all proposals by a large majority
GENEVA (June 12, 2025) – RELIEF THERAPEUTICS Holding ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.06.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Results of Annual General Meeting
News Preview
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, toda...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.05.2025
RLF
LISTED
SIX
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
News Preview
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA (May 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.05.2025
RLF
LISTED
SIX
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has grant...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
RLF
LISTED
SIX
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
News Preview
Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
GENEVA (MAY 15, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharma......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.05.2025
RLF
LISTED
SIX
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
RLF
LISTED
SIX
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
News Preview
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
GENEVA (APR. 10, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report an......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.04.2025
RLF
LISTED
SIX
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update. In his annual l...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.03.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
News Preview
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
GENEVA (March 6, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussi......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.03.2025
RLF
LISTED
SIX
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussions regarding a potential merger with Renexxion, I...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.02.2025
RLF
LISTED
SIX
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
News Preview
Relief Therapeutics Holding SA
/ Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CEST
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Patent Secures Protection for RLF-TD011 in Epidermolysi......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.02.2025
RLF
LISTED
SIX
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
News Preview
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rar...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
RLF
LISTED
SIX
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
News Preview
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE® Rights ex-USSale of GOLIKE® Rights Outside the U.S. to Nutrisens
Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products
GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharm......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.01.2025
RLF
LISTED
SIX
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
News Preview
Sale of GOLIKE® Rights Outside the U.S. to NutrisensRelief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.12.2024
RLF
LISTED
SIX
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
News Preview
Relief Therapeutics Holding SA
/ Key word(s): Merger
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27.12.2024 / 07:00 CET/CEST
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
GENEVA (DEC. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY)......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.12.2024
RLF
LISTED
SIX
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today provided an update on the potential reverse merger with Renexxion, In...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.12.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
News Preview
Relief Therapeutics Holding SA
/ Key word(s): Study results
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16.12.2024 / 07:00 CET/CEST
Relief Therapeutics Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PK......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.12.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
News Preview
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU GOLIKE ®GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF )(OTCQB:RLFTF )(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company commi...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.12.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
News Preview
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation
GENEVA (DEC. 13, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering inn......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.12.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
News Preview
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB QuotationGENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.11.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
News Preview
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA (NOV. 11, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, t......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.11.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive final results from its proof-of-concept, investig...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2024
RLF
LISTED
SIX
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
News Preview
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
GENEVA (NOV. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced i......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2024
RLF
LISTED
SIX
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Ren...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
News Preview
Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
GENEVA (OCT. 29, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, O......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
News Preview
GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced the publication of a Plain Language Summary in Future Rare Diseas...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2024
RLF
LISTED
SIX
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
News Preview
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options
GENEVA (OCT. 25, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a b......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.10.2024
RLF
LISTED
SIX
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
News Preview
New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innov...
Themefolio
Profiler
Peergroup
© EQS Newswire
21.10.2024
RLF
LISTED
SIX
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
News Preview
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
GENEVA (OCT. 21, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, un......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.10.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
News Preview
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
GENEVA (OCT. 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare disea......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.10.2024
RLF
LISTED
SIX
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced promising preliminary results from its proof-of-concept, inv...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.10.2024
RLF
LISTED
SIX
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
News Preview
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
GENEVA (OCT. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseas......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.10.2024
RLF
LISTED
SIX
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / October 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported positive topline results from its proof-of-concept clinical s...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2024
RLF
LISTED
SIX
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
News Preview
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2024
RLF
LISTED
SIX
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
News Preview
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will r......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.09.2024
RLF
LISTED
SIX
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
News Preview
GENEVA, SWITZERLAND / ACCESSWIRE / September 23, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it will receive a $2 million milestone payment from SWK...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
